Friday, 14 Jun 2019

You are here

The RheumNow Week in Review – Methotrexate CIRT Study (5.25.18)

Dr. Jack Cush reviews this past week's news from RheumNow.com - the risk of Cutaneous and Systemic LE, increasing flu vaccination, higher risk of VTE, MPO predictions, new drug for GIOP and CIRT - MTX in cardiovascular risk patients.

  1. Population study in Denmark shows the incidence of cutaneous LE to be 2.74/100,000 with a female:male ratio of 4:1 - the 10 year risk of these subsequently developing a dx of SLE was 12.9% (highest in women & SCLE pts) http://bit.ly/2IGoPQB
  2. Registry of 509 women with SLE had 719 children showed that compared to matched controls, children born to mothers with SLE had No greater risk of a systemic rheumatic autoimmune diagnoses. http://bit.ly/2GO37V0
  3. NEJM study of 1945 Kawasakis pts with >60% of pts < 4 months of age having onset in summer and fall in more. but > 60% of thos over 83 months had onset in winter and spring https://t.co/HAG9ZvQy8A
  4. Sandoz announces the approval of its infliximab biosimilarZessly (infliximab) by the European Commission. It is approved for use in RA, , adult & pediatric Crohn’s, adult & pediatric ulcerative colitis, AS, PsA and plaque psoriasis https://t.co/V0PJHbeLSp
  5. Not all that clear what is the best PFT for pts w/ Scleroderma Lung Disease, Some prefer the FVC, while others advocate for the DLCO or TLC. Do all 3! https://t.co/xNkpgGiYsv
  6. >50% of RA pts fail to receive influenza vaccination (highest in Younger, infrequent visits, Hi ESR, negative vaccine views). The problem was cut in half by using a multimodal intervention (education, EMR alerts, weekly provider-e-mail reminders) https://t.co/H8BxrLVAri
  7. Study of 85 RA patients demonstrates a prothrombotic tendency that is predicted by those with higher DAS-28, CRP, and platelet counts. https://t.co/wqU8XNzIDK
  8. Based on the recommendation of the Data Monitoring Committee, Regeneron has halted its phase III trial of fasinumab (anti- Nerve Growth Factor mAb), in OA pts w/ knee, hip or low back pain. https://t.co/ZwyjJbNzjm
  9. Paul Ridker, MD announced the NIH stopped enrolling the CIRT trial; MTX vs PBO in high risk (non-RA) pts looking at CV outcomes. DSMB rec. stopping after 4,786/7000 enrolled, not for safety, but because of enough efficacy data. Look for results in 11/18 https://t.co/n4PGybItkS
  10. RA pts have a 2 fold risk of osteoporosis-related fractures. High titer CCP levels assoc. w/ lower BMD and lean body mass assoc w/ higher BMD https://t.co/3cxPaiNIn6
  11. FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis 
  12. MPO Antibodies Predict Relapses in MPO-ANCA-Associated Vasculitis 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Ultrasound Reveals Which Anti-CCP Positive Patients Progress to Arthritis 

Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rheumatic and Musculoskeletal Medicine presented at EULAR 2019.

EULAR 2019 – Day 3 Report

The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019.

1. Genovese Vagal nerve stimulator in RA

2. Low dose steroids in Hand OA

EULAR 2019 Report – Day 2

It was a full and lively 2nd day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day 2 EULAR in Madrid 

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed.